| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
| Targets |
(S)-Dolaphenine hydrochloride does not have a defined pharmacological target as a standalone compound. It is a component of Dolastatin 10, which targets tubulin and inhibits its polymerization. Dolastatin 10 is an antineoplastic agent. As a building block, (S)-dolaphenine hydrochloride is used in the synthesis of various bioactive compounds. Its activity is context-dependent and related to the final compounds synthesized from it.
|
|---|---|
| ln Vitro |
In vitro, (S)-dolaphenine hydrochloride as a standalone compound does not have reported biological activity. Its primary use is as a synthetic building block for the preparation of Dolastatin 10 and other compounds. Dolastatin 10, which contains (S)-dolaphenine as a component, inhibits tubulin polymerization and has potent antineoplastic activity. The compound's in vitro activity is therefore indirect and related to the final products synthesized from it.
|
| ln Vivo |
In vivo activity of (S)-dolaphenine hydrochloride as a standalone compound has not been characterized. The compound is a building block used in chemical synthesis rather than a therapeutic agent. Dolastatin 10, which contains (S)-dolaphenine as a component, has antineoplastic activity in vivo. However, the standalone compound is not used in vivo.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays are not applicable to (S)-dolaphenine hydrochloride as a standalone compound, as it is not a bioactive molecule designed to interact with biological targets. The compound is a synthetic building block used in chemical synthesis. No standard binding assays have been developed or performed for this compound.
|
| Cell Assay |
In vitro cell-based assays are not applicable to (S)-dolaphenine hydrochloride as a standalone compound. The compound is a synthetic building block used in chemical synthesis. It is not used in cell biology research applications as a standalone compound. Dolastatin 10, which contains (S)-dolaphenine as a component, is studied in cell-based assays for its antineoplastic activity.
|
| Animal Protocol |
In vivo animal studies are not applicable to (S)-dolaphenine hydrochloride as a standalone compound. The compound is a synthetic building block used in chemical synthesis. It is not administered to animals for research purposes as a standalone compound. Dolastatin 10, which contains (S)-dolaphenine as a component, is studied in animal models.
|
| ADME/Pharmacokinetics |
Pharmacokinetic (PK) properties of (S)-dolaphenine hydrochloride as a standalone compound have not been characterized. The compound is a synthetic building block used in chemical synthesis. Its PK properties are not relevant to its intended applications. Dolastatin 10, which contains (S)-dolaphenine as a component, has its own PK profile.
|
| Toxicity/Toxicokinetics |
The toxicity profile of (S)-dolaphenine hydrochloride as a standalone compound has not been characterized. The compound is a synthetic building block used in chemical synthesis. Standard safety precautions for handling chemical intermediates should be followed. The compound is intended for research use only and is not approved for human therapeutic applications.
|
| References | |
| Additional Infomation |
(S)-Dolaphenine hydrochloride is a research-grade chemical building block used in the synthesis of Dolastatin 10 and other bioactive compounds. It has a molecular formula of C₁₁H₁₃ClN₂S and a molecular weight of 240.75. The compound is also known as (S)-2-phenyl-1-(thiazol-2-yl)ethanamine hydrochloride. Dolastatin 10, which contains (S)-dolaphenine as a component, inhibits tubulin polymerization and has antineoplastic activity. The compound is not an approved therapeutic drug. It is supplied as a high-purity powder (≥95-98%) and should be stored at -20°C.
|
| Molecular Formula |
C11H13CLN2S
|
|---|---|
| Molecular Weight |
240.752320051193
|
| Exact Mass |
240.048
|
| CAS # |
135383-60-7
|
| PubChem CID |
91971232
|
| Appearance |
Light yellow to yellow solid powder
|
| LogP |
3.887
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
15
|
| Complexity |
169
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C1=CC=C(C=C1)C[C@@H](C2=NC=CS2)N.Cl
|
| InChi Key |
XQCUEKANDANWHG-PPHPATTJSA-N
|
| InChi Code |
InChI=1S/C11H12N2S.ClH/c12-10(11-13-6-7-14-11)8-9-4-2-1-3-5-9;/h1-7,10H,8,12H2;1H/t10-;/m0./s1
|
| Chemical Name |
(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethanamine;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 50 mg/mL (~207.68 mM)
H2O : ≥ 50 mg/mL (~207.68 mM) |
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.1537 mL | 20.7684 mL | 41.5369 mL | |
| 5 mM | 0.8307 mL | 4.1537 mL | 8.3074 mL | |
| 10 mM | 0.4154 mL | 2.0768 mL | 4.1537 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
